Amgen Inc. (AMGN)
NASDAQ • Healthcare
April 2, 2026 at 20:00 UTC
About Amgen Inc.
Amgen Inc. is a biotechnology company focused on discovering, developing, and marketing medicines for serious illnesses across immunology, oncology, cardiometabolic disease, and other therapeutic areas. The company’s expertise spans biologics, targeted therapies, and biosimilars, supported by research platforms in protein engineering and human genetics. Commercial operations include physician education, patient access programs, and collaborations with health systems that emphasize safe and appropriate use of therapies. Amgen distributes products in North America, Europe, and additional regions through a mix of direct channels and partners. Positioned within the healthcare sector, the company’s work reflects the growing role of biotechnology in addressing complex medical needs and advancing precision approaches to treatment.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Amgen Inc.'s Technical Indicators Summary
Amgen carries a bearish technical tilt marked by weakening momentum and negative moving-average alignment in the short term. MACD and momentum are both negative and short-term averages sit above the current price, while the stock remains above longer-term averages, creating a mixed medium/long-term backdrop. ADX is modest, so there is not a powerful trend, but OBV is negative and the pivot and resistance levels are favoring sellers. Volatility is moderate, suggesting orderly selling pressure. Technical takeaway: Bearish — short-term weakness reinforced by negative momentum and declining volume.
| Indicator | Value |
|---|---|
RSI (14) | 39.39 |
Stochastic %K (14, 3, 3) | 21.40 |
CCI (20) | -69.42 |
WPR (14) | -88.47 |
Momentum (10) | -1.98 |
MFI | 26.57 |
MACD Level (12, 26) | -4.71 |
Bollinger Bands | $336.99 - $379.64 |
ATR (14) | $7.93 (2.28%) |
ADX (14) | 19.61 |
OBV | 40,495,000 |
Classic Pivot Point | $353.98 |
Fibonacci Pivot Point | $353.98 |
Exponential Moving Averages | $324.34 - $356.62(5 indicators) |
Simple Moving Averages | $319.22 - $363.14(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
By the final tick, the peer group was just a bit lower at -0.62%, reflecting a mild risk-off tilt. The day wrapped with modest participation in AMGN, as overall volume reached only 0.50× average. AMGN held a mostly flat session amid a mild risk-off in the peer group, with volume well below its average.
Price Change
from $347.94 close
+$0.05
Trading Volume
Below avg (3.1M)
1.5M
vs S&P 500 Today
Strong Underperformance
-5.45%
52-Week Position
Upper range
66.6%
Updated: April 3, 2026 at 20:01 UTC
Quote Summary
AMGN Headlines
Amgen and Gilead Face Conflicting Valuation Signals
March 12, 2026
Investors Confront Conflicting Valuation Signals
February 23, 2026
Live Nation, PTC, AES Lead Busy Earnings and Energy News
February 19, 2026
Biopharma Leaders Map Growth at JPM 2026
January 13, 2026